Company Overview of Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...
50 Tice Boulevard
Woodcliff Lake, NJ 07677
Founded in 2007
Key Executives for Eagle Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $449.6K
Chief Financial Officer
Total Annual Compensation: $265.9K
Chief Medical Officer and Head of Research & Development
Total Annual Compensation: $303.8K
Chief Scientific Officer
Total Annual Compensation: $352.4K
Compensation as of Fiscal Year 2014.
Eagle Pharmaceuticals Inc. Key Developments
Teva and Eagle Pharmaceuticals Announce NDA for Bendamustine Rapid Infusion Product Accepted for Filing
Apr 14 15
Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals Inc. announced that the New Drug Application for a liquid bendamustine hydrochloride (HCl) rapid infusion product has been accepted for filing by the U.S. Food and Drug Administration. This NDA requests FDA approval of the rapid infusion bendamustine HCl product for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. This product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval. The NDA is supported by data from a clinical trial completed in November 2014, which demonstrated that the rapid infusion bendamustine HCl product can be administered in ten minutes in a low-volume, 50 mL admixture.
Eagle Pharmaceuticals Inc. Appoints David M. Pernock as Board of Directors
Apr 13 15
Eagle Pharmaceuticals Inc. announced that David M. Pernock, an experienced biotechnology and pharmaceutical executive with over 25 years of industry experience, has been appointed to its board of directors effective immediately. Mr. Pernock is chief executive officer and chairman of the board of Fibrocell Science Inc. Prior to Fibrocell, Mr. Pernock held several positions during his 17-year tenure at GlaxoSmithKline, including: senior vice president of Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions; vice president of marketing, Pharmaceuticals; vice president of sales and marketing, Oncology; vice president of sales; and vice president of managed care. Previously, Mr. Pernock was vice president of marketing Wyeth Pharmaceuticals and Schering-Plough Corporation, and vice president of sales and marketing at Key Pharmaceuticals. In addition to his role as chairman of the board of Fibrocell Science Inc., Mr. Pernock served on the boards of Martek Biosciences Corporation and the Alliance for Regenerative Medicine. Mr. Pernock was elected to fill a vacancy on the board and will serve as a Class I director with a term of office expiring at the company’s 2015 annual meeting of stockholders.
Eagle Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM
Mar 25 15
Eagle Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: David E. Riggs, Chief Financial Officer, Scott L. Tarriff, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|